# Blood Pressure Control in GLP-1 Users: What 45 Survey Responses Show

Why a national survey with 45 GLP-1 users cannot establish whether treatment improves blood pressure control.

Publisher: Buy This GLP Editorial Team
Canonical: https://buythisglp.com/research/forty-five-people-and-a-national-estimate
Updated: 2026-11-15
Published: 2026-09-17

[← Research](https://buythisglp.com/research)

Evidence

# Blood Pressure Control in GLP-1 Users: What 45 Survey Responses Show

A national survey found a gap in blood pressure control. Only 45 respondents reported GLP-1 use.

Editorial profile: [Neil Sanders](https://buythisglp.com/authors/neil-sanders)[Buy This GLP Editorial Team](https://buythisglp.com/about)September 20264 min readUpdated November 2026

NHANES, 2017 to March 2020 · 45 · 4,016 · Reported GLP-1 use · Adults with hypertension in the sample

**Research, not medical advice.** Buy This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://buythisglp.com/methodology) and [terms](https://buythisglp.com/terms).

## Key takeaways

-   The survey included 4,016 adults with hypertension. Only 45 reported GLP-1 use.
-   The weighted share with blood pressure below 130/80 mmHg was 66% among users and 24% among nonusers.
-   The snapshot cannot establish whether taking a GLP-1 accounts for the difference.

Trials on [GLP-1 drugs and blood pressure](https://buythisglp.com/research/do-glp1-drugs-lower-blood-pressure) measure changes after treatment starts. This national survey compared people at one point in time. It found differences that a randomized trial would need to put in context.

## What the survey counted

The analysis used NHANES data from 2017 to March 2020. It included 4,016 U.S. adults with hypertension. Of those, 45 reported using a GLP-1 drug [\[1\]](https://buythisglp.com/research/forty-five-people-and-a-national-estimate#ref-1).

The estimated share below both 130 systolic and 80 diastolic was 66% among users and 24% among nonusers. After applying survey weights, the 45 users represented an estimated 994,028 adults[\[1\]](https://buythisglp.com/research/forty-five-people-and-a-national-estimate#ref-1). The weights account for how people were sampled. The precision still depends on the number of respondents and the survey design [\[2\]](https://buythisglp.com/research/forty-five-people-and-a-national-estimate#ref-2).

## Why the groups are hard to compare

The weighted share with diabetes was 99% among users and 18% among nonusers. Average BMI was also higher among users, at 37.25 versus 31.22 [\[1\]](https://buythisglp.com/research/forty-five-people-and-a-national-estimate#ref-1). The groups differed substantially before considering blood pressure. The survey cannot show whether the difference came from the drug or other factors.

## What randomized trials measured

A separate analysis used individual data from three semaglutide trials. Systolic blood pressure fell about 5 mmHg more with semaglutide than with placebo [\[3\]](https://buythisglp.com/research/forty-five-people-and-a-national-estimate#ref-3). That measures the average change in systolic pressure. It cannot tell us how many people reached the survey cutoff.

## Sources

1.  \[1\] Elfezzani N, Mambu TM, Nnanna JU, Iwu II, Nedassa BW, Nathan-Otu E (2026). Blood Pressure Control Among U.S. Adults With Hypertension, Stratified by Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Use: Evidence From the National Health and Nutrition Examination Survey, 2017-2020 Cureus. [PMID 42662789](https://pmc.ncbi.nlm.nih.gov/articles/PMC13520756/)
2.  \[2\] National Center for Health Statistics (2026). NHANES Tutorials: Reliability of Estimates Centers for Disease Control and Prevention. [Source](https://wwwn.cdc.gov/nchs/nhanes/tutorials/ReliabilityOfEstimates.aspx)
3.  \[3\] Kennedy C, et al. (2024). Semaglutide and blood pressure: an individual patient data meta-analysis European Heart Journal. [Source](https://academic.oup.com/eurheartj/article/45/38/4124/7745627)

## Where to get it

### Price the injectable sellers

The desk lists every seller that publishes an injectable figure, with the advertised price struck against the one a buyer is billed.

[Open the price desk →](https://buythisglp.com/)

## More in Evidence

-   [
    
    50,678 adults with a BMI of 30 or more · Prescribed · 8.0% · Filled · 4.4% · Outlined bar runs to 10%. Medicaid had lower odds of both.
    
    ### Does Medicaid Cover Weight Loss Drugs? It Depends on Your State
    
    ](https://buythisglp.com/research/does-medicaid-cover-weight-loss-drugs)
-   [
    
    What the claim rests on · Sleep study · AHI 15 or more · Obesity · BMI 30 or more · Prescription · for sleep apnea · Part D claim · plan review · Trial thresholds shown. Your plan sets its approval requirements.
    
    ### Does Medicare Cover Zepbound for Sleep Apnea? The Diagnosis Is the Key
    
    ](https://buythisglp.com/research/does-medicare-cover-zepbound-for-sleep-apnea)
-   [
    
    Illustrative decline with a one-week half-life · Ozempic window: up to 5 days late · 100% · day 0 · 82% · day 2 · 67% · day 4 · 61% · day 5 · 50% · day 7 · A calculation from the label half-life, not a blood test.
    
    ### What Happens If You Miss a Dose of Ozempic? A Week-Long Half-Life Buys Time
    
    ](https://buythisglp.com/research/what-happens-if-you-miss-a-dose-of-ozempic)
